 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Haemonetics Corporation (HAE) provides medical products and solutions. 
It operates through three segments: Plasma, Blood Center, and Hospital.
The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system.
In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries.
On August 10th, HAE reported 1st Quarter June 2022 earnings of $0.58 per share on revenue of $261.5 million. The consensus earnings estimate was $0.53 per share on revenue of $255.4 million. Revenue grew 14.4% on a year-over-year basis.
The company guided higher for the year. It now expects fiscal 2023 earnings of $2.60 to $2.90 per share on revenue of $1.073 billion to $1.102 billion. The company's previous guidance was earnings of $2.50 to $2.90 per share on revenue of $1.05 billion to $1.09 billion. The next report is November 7th. Shares have formed a bullish "wedge" and are expected to move higher from this formation.
Entry Point: $78.50
Stop Loss: $75.00
Trading Range: $43.50 to $80.93
Target Price: $86.00
